Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2002 Jan;57(1):11–14. doi: 10.1136/thorax.57.1.11

Practice, efficacy and cost of staging suspected non-small cell lung cancer: a retrospective study in two Dutch hospitals

G Herder 1, P Verboom 1, E Smit 1, P C M van Velthoven 1, J H A M van den Bergh 1, C Colder 1, I van Mansom 1, J C van Mourik 1, P Postmus 1, G Teule 1, O Hoekstra 1
PMCID: PMC1746187  PMID: 11809983

Abstract

Background: A study was undertaken to investigate the clinical practice, yield, and costs of preoperative staging in patients with suspected NSCLC and to obtain baseline data for prospective studies on the cost effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the management of these patients.

Methods: A retrospective study of the medical records of all patients with suspected NSCLC was performed during a 2 year interval (1993–4) in an academic and a large community hospital.

Results: Three hundred and ninety five patients with suspected NSCLC were identified; 58 were deemed to be medically inoperable and 337 patients proceeded to the staging process. Staging required a mean (SD) of 5.1 (1.5) diagnostic tests per patient (excluding thoracotomy) carried out over a median period of 20 days (IQR 10–31). Many of the tests (including both invasive and non-invasive) were done because previous imaging tests had suggested metastases, and in most cases the results of initial tests proved to be false positives. After clinical staging, 168 patients were considered to be resectable (stage I/II) and 144 patients underwent surgery with curative intent. At surgery 33 patients (23% of those who underwent surgery) were found to have irresectable lesions and 19 (13%) had a benign lesion. Surgery was also considered to be futile in 22 patients (15%) who developed metastases or local recurrence within 12 months following radical surgery. Hospital admission was responsible for most of the costs.

Conclusion: In many patients staging involved considerable effort in terms of the number of diagnostic tests, the duration of the staging period and the cost, with limited success in preventing futile surgery. Failures relate to the quality of diagnostic preparation at every level of the TNM staging system.

Full Text

The Full Text of this article is available as a PDF (110.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dwamena B. A., Sonnad S. S., Angobaldo J. O., Wahl R. L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology. 1999 Nov;213(2):530–536. doi: 10.1148/radiology.213.2.r99nv46530. [DOI] [PubMed] [Google Scholar]
  2. Fergusson R. J., Gregor A., Dodds R., Kerr G. Management of lung cancer in South East Scotland. Thorax. 1996 Jun;51(6):569–574. doi: 10.1136/thx.51.6.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Goldstraw P., Rocmans P., Ball D., Barthelemy N., Bonner J., Carette M., Choi N., Emami B., Grunenwald D., Hazuka M. Pretreatment minimal staging for non-small cell lung cancer: an updated consensus report. Lung Cancer. 1994 Nov;11 (Suppl 3):S1–S4. doi: 10.1016/0169-5002(94)91856-2. [DOI] [PubMed] [Google Scholar]
  4. Grimshaw J. M., Russell I. T. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993 Nov 27;342(8883):1317–1322. doi: 10.1016/0140-6736(93)92244-n. [DOI] [PubMed] [Google Scholar]
  5. Lacasse Y., Bucher H. C., Wong E., Griffith L., Walter S., Ginsberg R. J., Guyatt G. H. "Incomplete resection" in non-small cell lung cancer: need for a new definition. Canadian Lung Oncology Group. Ann Thorac Surg. 1998 Jan;65(1):220–226. doi: 10.1016/s0003-4975(97)01190-9. [DOI] [PubMed] [Google Scholar]
  6. Miller J. D., Gorenstein L. A., Patterson G. A. Staging: the key to rational management of lung cancer. Ann Thorac Surg. 1992 Jan;53(1):170–178. [PubMed] [Google Scholar]
  7. Pieterman R. M., van Putten J. W., Meuzelaar J. J., Mooyaart E. L., Vaalburg W., Koëter G. H., Fidler V., Pruim J., Groen H. J. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000 Jul 27;343(4):254–261. doi: 10.1056/NEJM200007273430404. [DOI] [PubMed] [Google Scholar]
  8. Tsang G. M., Watson D. C. The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer. Thorax. 1992 Jan;47(1):3–5. doi: 10.1136/thx.47.1.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Tugwell P., Bennett K. J., Sackett D. L., Haynes R. B. The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis. 1985;38(4):339–351. doi: 10.1016/0021-9681(85)90080-3. [DOI] [PubMed] [Google Scholar]
  10. van Tinteren H., Hoekstra O. S., Smit E. F., Verboom P., Boers M., PLUS Study Group Toward less futile surgery in non-small cell lung cancer? A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography. Control Clin Trials. 2001 Feb;22(1):89–98. doi: 10.1016/s0197-2456(00)00119-7. [DOI] [PubMed] [Google Scholar]
  11. van Zandwijk N. Consensusbijeenkomst diagnostiek longcarcinoom. Ned Tijdschr Geneeskd. 1991 Oct 12;135(41):1915–1919. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES